Oxidative stress in white coat hypertension; role of paraoxonase

Journal of Human Hypertension

Volumn 18, Issue 7, 2004, Pages 523-528

  Uzun, H ^a   Karter, Y ^a   Aydin, S ^a   Curgunlu A ^a   Simsek G ^a   Yucel R ^a   Vehiyd, S ^a   Erturk N ^a   Kutlu, A ^b   Benian, A ^a   Yaldiran, A ^a   Ozturk E ^a   Erdine, S ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Department of Biochemistry   (Turkey)

Author keywords

Hypertension; Malondialdehyde (MDA); Oxidative stress; Oxidized low density lipoprotein(oxLDL); Paraoxonase (PON1); White coat hypertension

Indexed keywords

ARYLDIALKYLPHOSPHATASE; LIPID; MALONALDEHYDE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; WHITE COAT HYPERTENSION;

ADULT; ARYLDIALKYLPHOSPHATASE; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CASE-CONTROL STUDIES; DIASTOLE; FEMALE; HUMANS; HYPERTENSION; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; OFFICE VISITS; OXIDATIVE STRESS; SYSTOLE;

EID: 3543083866     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001697     Document Type: Article

References (35)

1. Sagar S et al. Oxygen free radicals in essential hypertension. Mol Cell Biochem 1992; 111 (1-2): 103-108.
2. Koska J et al. Malondialdehyde, lipofuscin and activity of antioxidant enzymes during physical exercise in patients with essential hypertension. J Hypertens 1999; 17 (4): 529-535.
3. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation 1997; 95 (4): 1062-1071.
4. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344 (17): 793-795.
5. Li D, Mehta JL. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect against oxidized low-density lipoprotein induced endothelial dysfunction. Endothelium 2003; 10 (1): 17-21.
6. Mackness Ml et al. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7 (2): 69-76.
7. Aviram M et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. J Clin Invest 1998; 101 (8): 1581-1590.
8. Rozenberg O et al. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003; 34 (6): 774-784.
9. Sözmen B, Delen Y, Girgin FK, Sözmen EY. Catalase and paraoxonase in hypertensive type 2 diabetes mellitus: correlation with glycemic control. Clin Biochem 1999; 32 (6): 423-427.
10. Laplaud PM, Dantoine T, Chapman MJ. Paraoxonase as a risk marker for cardiovascular disease: facts and hypothesis. Clin Chem Lab Med 1998; 36 (7): 431-441.
11. Mackness B et al. Paraoxonase status in coronary heart disease. Arterioscler Thromb Vasc Biol 2001; 21: 1451-1457.
12. Cardillo C, De Felice F, Campia U, Folli G. Psychophysiological reactivity and cardiac end-organ changes in white coat hypertension. Hypertension 1993; 21 (6 Part 1): 836-844.
13. Bjorklund K et al. Different metobolic predictors of white-coat and sustained hypertension over a 20-year follow up period: a population-based study of elderly men. Circulation 2002; 106 (1): 63-68.
14. Julius S et al. 'White coat' versus 'sustained' borderline hypertension in Tecumseh, Michigan. Hypertension 1990; 16 (6): 617-623.
15. Cardillo C, De Felice F, Campia U, Folli G. Psychophysiological reactivity and cardiac end-organ changes in white coat hypertension. Hypertension 1993; 21 (6 Part 1): 836-844.
16. No authors listed. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. American Society of Hypertension. Am J Hypertens 1992; 5 (4): 207-209.
17. Ramsay LE et al, for the British Hypertension Society. BHS Guidelines for the management of hypertension: report of third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-592.
18. Alderman M et al. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17 (2): 151-185.
19. O'Brien E et al. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001; 322 (7285): 531-536.
20. O'Brien E et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ 2000; 320 (7242): 1128-1134.
21. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978; 52: 302-310.
22. Hasselwander O et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 1999; 56 (1): 289-298.
23. Saha N et al. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 1991; 40 (4): 277-282.
24. Newaz MA, Nawal NN. Effect of gamma-tocotrienol on blood pressure, lipid peroxidation and total antioxidant status in spontaneously hypertensive rats (SHR). Clin Exp Hypertens 1999; 21 (8): 1297-1313.
25. Uddin M et al. Elevation of oxidative stress in the aorta of genetically hypertensive mice. Mech Ageing Dev 2003; 124 (7): 811-817.
26. Kumar CA, Das UN. Lipid peroxides, anti-oxidants and nitric oxide in patients with pre-eclampsia and essential hypertension. Med Sci Monit 2000; 6 (5): 901-907.
27. Suzuki H et al. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci USA 1998; 95 (8): 4754-4759.
28. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 2001; 38 (5): 1107-1111.
29. Djordjevic VB et al. Changes of lipid peroxides and antioxidative factors levels in blood of patients treated with ACE inhibitors. Clin Nephrol 1997; 47 (4): 243-247.
30. Torrecillas G et al. The role of hydrogen peroxide in the contractile response to angiotensin II. Mol Pharmacol 2001; 59 (1): 104-112.
31. Redon J et al. Antioxidant activities and oxidative stress byproduct in human hypertension. Hypertension 2003; 41 (5): 1096-1101.
32. Pierdomenico SD et al. Low density lipoprotein oxidation and vitamins E and C in sustained and white coat hypertension. Hypertension 1998; 31: 621-636.
33. Gomez GR et al. Noninvasive study of endothelial function in white coat hypertension. Hypertension 2002; 40 (3): 304-309.
34. Karter Y et al. Endothelial dysfunction in sustained and white coat hypertension. Am J Hypertens 2003; 16 (10): 892.
35. Antonicelli R et al. Relationship between lipoprotein(a) levels, oxidative stress, and blood pressure levels in patients with essential hypertension. Clin Exp Med 2001; 1 (3): 145-150.